Nautilus Biotechnology (NAUT) Long-Term Investments (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Long-Term Investments data on file, last reported at $47.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 12.07% year-over-year to $47.5 million; the trailing twelve-month figure through Mar 2026 stood at $47.5 million (down 12.07% YoY), and the FY2025 full-year result was $52.7 million, down 30.97% from the prior year.
• Long-Term Investments retreated to $47.5 million in Q1 2026, from $52.7 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $134.6 million in Q1 2023 to a low of $24.9 million in Q1 2022.
• A 5-year average of $71.1 million and a median of $65.7 million in 2022 frame the typical range for Long-Term Investments.
• Peak annual rise in Long-Term Investments reached 689.01% in 2022, while the deepest fall reached 83.34% in 2022.
• Tracing NAUT's Long-Term Investments over 5 years: stood at $129.2 million in 2022, then fell by 29.82% to $90.6 million in 2023, then retreated by 15.71% to $76.4 million in 2024, then slumped by 30.97% to $52.7 million in 2025, then declined by 9.92% to $47.5 million in 2026.
• Business Quant data shows NAUT's Long-Term Investments at $47.5 million in Q1 2026, $52.7 million in Q4 2025, and $37.1 million in Q3 2025.